Published in Hepatitis Weekly, November 18th, 2002
The company's AERx system is its inhaled drug delivery product. AERx iDMS is the company's diabetes drug delivery system.
"This quarter marked a major milestone in the company's history as AERx iDMS, our most advanced development program, entered phase III clinical trials," said Richard Thompson, Aradigm Corporation. "We are very pleased with the safety data and successful clinical results to date from the iDMS program and with the support provided by our partner Novo...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly